Orchestra BioMed reports 2022 net loss of $33.6M; revenue up to $3.5M from negative prior year

Orchestra BioMed Holdings, Inc.

Net loss was $33.6M for 2022 vs $23.0M in 2021; operating expenses rose to $36.2M.
Revenue of $3.5M included $2.9M partnership revenue; product revenue flat at $0.7M.
Cash and marketable securities totaled $83.7M at Dec 31, 2022, up from $9.9M; funded by Series D preferred stock.
Accumulated deficit reached $199.7M; management expects continued losses but has sufficient liquidity post-merger.
Business combination with HSAC2 (SPAC) closed Jan 2023; audited financials now filed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Orchestra BioMed Holdings, Inc. reported financial results for the fiscal year ended December 31, 2022.

Period: the fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

Item 2.02. Results of Operations and Financial Condition. The financial statements set forth under paragraph (a)(1) of Item 9.01 of this Current Report on Form 8-K are incorporated herein by reference.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Orchestra BioMed Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-022800

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.